- Home
- ISRL vs ACHV Comparison
ISRL vs ACHV Comparison
Compare ISRL & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISRL
- ACHV
- Stock Information
- Founded
- ISRL 2021
- ACHV N/A
- Country
- ISRL United States
- ACHV Canada
- Employees
- ISRL N/A
- ACHV N/A
- Industry
- ISRL Blank Checks
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ISRL Finance
- ACHV Health Care
- Exchange
- ISRL Nasdaq
- ACHV Nasdaq
- Market Cap
- ISRL 143.1M
- ACHV 159.0M
- IPO Year
- ISRL 2023
- ACHV N/A
- Fundamental
- Price
- ISRL $11.23
- ACHV $5.05
- Analyst Decision
- ISRL
- ACHV Strong Buy
- Analyst Count
- ISRL 0
- ACHV 4
- Target Price
- ISRL N/A
- ACHV $15.50
- AVG Volume (30 Days)
- ISRL 44.1K
- ACHV 118.6K
- Earning Date
- ISRL 01-01-0001
- ACHV 11-07-2024
- Dividend Yield
- ISRL N/A
- ACHV N/A
- EPS Growth
- ISRL 33.17
- ACHV N/A
- EPS
- ISRL 0.29
- ACHV N/A
- Revenue
- ISRL N/A
- ACHV N/A
- Revenue This Year
- ISRL N/A
- ACHV N/A
- Revenue Next Year
- ISRL N/A
- ACHV N/A
- P/E Ratio
- ISRL $38.48
- ACHV N/A
- Revenue Growth
- ISRL N/A
- ACHV N/A
- 52 Week Low
- ISRL $10.57
- ACHV $3.03
- 52 Week High
- ISRL $11.24
- ACHV $5.98
- Technical
- Relative Strength Index (RSI)
- ISRL 65.14
- ACHV 61.03
- Support Level
- ISRL $11.14
- ACHV $4.85
- Resistance Level
- ISRL $11.23
- ACHV $5.19
- Average True Range (ATR)
- ISRL 0.02
- ACHV 0.20
- MACD
- ISRL -0.00
- ACHV 0.00
- Stochastic Oscillator
- ISRL 100.00
- ACHV 65.67
About ISRL Israel Acquisitions Corp
Israel Acquisitions Corp is a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.